The Dexcom G6 continuous glucose monitoring (CGM) system received FDA marketing approval March 27, the agency announced. This is the first system permitted by the FDA to be used in an “integrated” fashion alongside other diabetes management devices, including automatic insulin dosing systems, insulin pumps and blood glucose meters.
Santa Monica, CA, March 28, 2018 — BioSig Technologies, Inc. (OTCQB: BSGM) announced that the Company has filed 510(k) application to the U.S. Food and Drug Administration (FDA) for its first product, PURE EP(TM) System.
Individuals whose diets are rich in plant-based monounsaturated fatty acids are associated with a lower risk of dying from heart disease or other causes in comparison to animal-based diets rich in monounsaturated fats, according to preliminary findings presented at the American Heart Association’s Epidemiology and Prevention | Lifestyle and Cardiometabolic Health Scientific Sessions 2018 on March 21 in New Orleans.
A visor-like wearable device detected emergent large vessel occlusion (ELVO) with 92 percent accuracy in a study of 248 individuals, outperforming standard neurologic assessment tools based on physical examination.
A new study out of Australia demonstrates rats’ heart cells not only get bigger as a result of exercise, but they can also increase in number when endurance training takes place at young ages. What’s more, the additional cells remain present into adulthood, even after the rats have become sedentary.
A vocal minority who are opposed to using tissue plasminogen activator (TPA) for treating strokes is contributing to fewer patients receiving the clot-busting drug, the New York Times reported.
BOCA RATON, Fla., March 27, 2018 — New research from MDVIP and Cleveland HeartLab finds that patients with diabetes, pre-diabetes or no evidence of diabetes whose physicians ordered myeloperoxidase (MPO) inflammation testing achieved sharp reductions in MPO levels over five years.
Though a significant amount of literature currently exists regarding high cholesterol as a risk factor for cardiovascular disease (CVD), less than 40 percent of people with high cholesterol levels are prescribed the correct drug treatments, according to new research published in the American Heart Association’s journal Circulation.
Two editors of JACC: Heart Failure detailed how the United States has fallen behind other countries in site-based clinical research and offered suggestions on how to reinvigorate the research culture in America.
